Missense mutations leading to ***** inactivation may also be sensitive to therapies that reactivate mutant p53 such as *****-246 (***** et *****., 2016; ***** Abstract 5571, ***** et *****., 2012; *****, ***** et *****., 2015; *****, ***** *****., 2016; *****).
